JAPAN PASSIVE: The Nikkei 225 Baskets if BOJ Changes
Last week in JAPAN PASSIVE: BOJ Heading For Trouble with Nikkei 225 I discussed the BOJ's past and current ETF purchasing selection, ownership,...
729 Views
Series of R&D Positives After Recent Late Stage Setbacks, However, Too Early to Draw Firm Conclusion
Cost rationalization effort to drive industry leading earnings growth (on almost flat sales) over next 3-5 years. We reiterate our Neutral rating...
224 Views
Domestic Business Driven FY17 Topline Growth Is Not Sustainable
Daiichi Sankyo Co Ltd (4568 JP)'s FY17 results Domestic pharma performance (up ~7% y-o-y to ¥613b and contribution up 400bps to 64% of total sales...
210 Views
Japan Pharma - FY17e Earnings Preview (I)
Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidance Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...
219 Views
Japan Pharmaceutical - Sector Overview
Core coverage – relative valuations Takeda Pharmaceutical Co Ltd (4502 JP) (NB: Pre-Shire announcement | Pro-Forma analysis to be published...
266 Views